JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.